ID

6181

Descrição

ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Link

http://clinicaltrials.gov/ct2/show/record/NCT00952588

Palavras-chave

  1. 14/11/2011 14/11/2011 -
  2. 06/12/2013 06/12/2013 - Martin Dugas
  3. 11/04/2014 11/04/2014 - Julian Varghese
  4. 16/12/2014 16/12/2014 - Martin Dugas
Transferido a

16 de dezembro de 2014

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility AZD1152 and LDAC in AML

Eligibility AZD1152 and LDAC in AML

Inclusion criteria
Descrição

Inclusion criteria

Alias
UMLS CUI-1
C1512693
Provision of written informed consent
Descrição

consent

Tipo de dados

boolean

Alias
UMLS CUI-1
C0021430
Newly diagnosed male or female patients aged 60 and over
Descrição

Newly diagnosed patients aged 60 and over

Tipo de dados

boolean

Alias
UMLS CUI-1
C0001779
De Novo or Secondary AML
Descrição

De Novo or Secondary AML

Tipo de dados

boolean

Alias
UMLS CUI-1
C0023467
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
Descrição

Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia

Tipo de dados

boolean

Alias
UMLS CUI-1
C3242266
UMLS CUI-2
C0600558
Exclusion criteria
Descrição

Exclusion criteria

Alias
UMLS CUI-1
C0680251
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Descrição

Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product

Tipo de dados

boolean

Alias
UMLS CUI-1
C2348568
Administration of LDAC is clinically contraindicated
Descrição

Administration of LDAC is clinically contraindicated

Tipo de dados

boolean

Alias
UMLS CUI-1
C1301624
UMLS CUI-2
C0010711
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Descrição

Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)

Tipo de dados

boolean

Alias
UMLS CUI-1
C0023487
Patients with blast crisis of chronic myeloid leukaemia
Descrição

Patients with blast crisis of chronic myeloid leukaemia

Tipo de dados

boolean

Alias
UMLS CUI-1
C0023473
UMLS CUI-2
C0005699

Similar models

Eligibility AZD1152 and LDAC in AML

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
consent
Item
Provision of written informed consent
boolean
C0021430 (UMLS CUI-1)
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
C0001779 (UMLS CUI-1)
AML
Item
De Novo or Secondary AML
boolean
C0023467 (UMLS CUI-1)
Patient not eligible for Induction therapy
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
C3242266 (UMLS CUI-1)
C0600558 (UMLS CUI-2)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
C2348568 (UMLS CUI-1)
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
C1301624 (UMLS CUI-1)
C0010711 (UMLS CUI-2)
AML M3 APL
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
C0023487 (UMLS CUI-1)
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
C0023473 (UMLS CUI-1)
C0005699 (UMLS CUI-2)

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial